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A B S T R A C T
Purpose: We examined whether early EEG changes in a 24-h EEG at 6 weeks of treatment were related to
the later clinical response to the ketogenic diet (KD) in a 6-month period of treatment.
Methods: We examined 34 patients with heterogeneous epilepsy syndromes (21 children, 13 adults) and
found 9 clinical responders (50% seizure reduction); this is a responder rate of 26%. We visually counted
the interictal epileptic discharge index (IED index) in % during 2 h of wakefulness and in the ﬁrst hour of
sleep (method 1), and also globally reviewed EEG changes (method 2), while blinded to the effect of the
KD.
Results: At group level we saw a correlation between nocturnal reduction of IED-index at 6 weeks and
seizure reduction in the follow-up period. A proportional reduction in IED index of 30% from baseline in
the sleep EEG, was associated with being a responder to the diet (Pearson Chi-square p = 0.04). EEG
scoring method 2 observed a signiﬁcantly larger proportion of patients with EEG-improvement in sleep
in KD responders than in non-responders (p = 0.03). At individual level, however, EEG changes did not
correlate very strongly to the response to the diet, as IED reduction in sleep was also seen in 15% (method
1) to 26% (method 2) of the non-responders.
Conclusion: Nocturnal reduction of IEDs is related to the response to the KD, however in daily clinical
practice, an early EEG to predict seizure reduction should not be advised for individual patients.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
The KD is a high-fat, low-protein, low-carbohydrate diet used to
treat patients with refractory epilepsy. The proportion of patients
with 50% seizure reduction varies from 38–62% at 3 months after
initiation of the KD to 27–58% at 6 months.1–6 A randomized,* Corresponding author at: Epilepsy Centre Kempenhaeghe, Department of
Neurology, PO Box 61, 5590 AB Heeze, The Netherlands. Tel.: +31 40 227 90 22;
fax: +31 40 226 56 91.
E-mail address: lambrechtsd@kempenhaeghe.nl (Danielle A.J.E. Lambrechts).
1 Both authors contributed equally to this study.
http://dx.doi.org/10.1016/j.seizure.2014.03.008
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights recontrolled trial showed that 28 patients of the KD group had
greater than 50% seizure reduction (38%), compared to four
controls (6%) and ﬁve of the KD group had greater than 90% seizure
reduction (7%), compared to none of the controls.7 There were no
statistically signiﬁcant differences in outcome between patients
treated with the MCT or classical KD.7–9 The results of 30 studies
with the MAD, of which one RCT demonstrated similar efﬁcacy to
the KD.7–9 Although it is traditionally children who are treated
with the KD, there is also evidence of its efﬁcacy in adults.6,10 The
exact mechanisms underlying the effectiveness of the KD have not
been elucidated. Because of the dietary changes, the KD is often
experienced as a burden. If the response to the KD could be
predicted in individual patients before or soon after its initiation,served.
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potentially beneﬁt from the KD and who should be encouraged to
continue the diet.
The frequency of interictal epileptic discharges (IEDs) is a
potential predictor for response to treatments. The occurrence of
IEDs is correlated to seizure recurrence.11,12 IED frequency is
correlated with seizure-frequency, especially in patients with
severe epilepsies.13 In a recent study Kessler et al.14 found that a
response to the diet was 6 times more likely in children with a
proportional IED index decline in wakefulness of 10% from
baseline at one month of KD treatment.
In our centre, adults as well as children are treated with the KD.
We examined whether early EEG changes during wakefulness or
sleep 6 weeks after treatment initiation could be used to predict
the response to the diet in subsequent months. We hypothesized
that if a reduction of IEDs is seen soon after the initiation of the KD,
this is related to a reduction in seizure frequency in subsequent
months. Secondly, we examined whether baseline characteristics
could predict the response to the KD.
2. Methods
2.1. Study design
We compared the IED-frequency in a 24-h ambulatory EEG after
6 weeks of treatment with the KD, to the IED-frequency in a
baseline 24-h EEG one week before treatment (Fig. 1). A period of 4
weeks treatment is necessary to obtain stable ketosis. We
registered at 6 weeks in order to be early in the treatment phase
together with a high chance of all patients being in a steady ketosis
at that moment.
A change in IED-frequency was compared with the clinical
outcome as deﬁned by the mean seizure frequency during a follow-
up period ranging from at least 2 to a maximum of 6 months
compared to 2 months baseline. Seizure counts in the ﬁrst month
of KD introduction were not used to deﬁne clinical outcome,
because this period was necessary to obtain ketosis.
Antiepileptic drugs (AED) were continued unchanged during
baseline and the ﬁrst six months of treatment with the KD. The
only allowed exception was an urgent medical reason.
The study was approved by the Medical Ethics Committee
according to Dutch Governmental Guidelines.Fig. 1. Study2.2. Ketogenic diet
The KD was introduced during a 2-week hospitalization
according to the Dutch guideline for KD15. This guideline does
not include a fasting period. Usually the MCT (medium chain
triglyceride)-diet was applied but if the insurance company did not
refund the diet products, or at the subject’s request, the classical
diet or modiﬁed Atkins diet (MAD) was used. Changes could be
made to the MCT-diet because of side-effects and other problems
during the introduction phase. When tube feeding was given, a
liquid form of the classical KD was used. The start of the diet was
deﬁned as the ﬁrst change made to the daily nutrition. During the
KD, ketosis was frequently measured. During the second 24-h EEG,
the ketosis was measured in urine and blood or only in blood in
cases of incontinence.
2.3. Clinical outcome
Patients and/or caregivers were asked to register seizures in a
diary starting two months prior to the introduction of the KD.
The mean seizure frequency during the follow-up period after
the 4 weeks of KD introduction was calculated and compared to the
baseline mean seizure frequency. When the mean seizure
frequency was reduced by 50%, the patient was deﬁned as being
a clinical responder. If seizure diaries were incomplete, the treating
physician was asked to deﬁne the patient as a responder or non-
responder, using patient’s and/or caregiver’s information.
2.4. EEG analysis
EEGs were recorded with the localizations Fp2, F4, C4, P4, O2,
F8, T4, T6, Fp1, F3, C3, P3, O1, F7, T3, T5, Fp0, F0, C0, and P0. For the
comparison of the IED-frequency before and after KD, two EEG
scoring methods were used.
2.4.1. EEG scoring method 1
The number of IEDs was visually counted during 2 h
of wakefulness (1 h during the day and the ﬁrst hour after
awakening). If possible, the selection was taken from the same
hours of the day for EEG 1 and EEG 2, to minimize the effects of
circadian rhythm or drug level ﬂuctuations on the IED index. The
mean number of IEDs in these 2 h was used to calculate a % of time
of IEDs: (number of seconds containing IEDs/total number of design.
Table 1a
Demography.
Patients, N 34
Male/female, N (%) 17/17 (50%/50%)
Mean age at KD initiation in years;months
(min–max value)
16;0 (1;1–45;5)
Number of children (age <18 years) at KD
initiation, N (%)
21 (62%)
Mean age at seizure onset in years;months
(min–max value)
5;0 (0;0–31;6)
Mean duration of epilepsy in years;months
(min–max value)
11;0 (1;3–44;11)
Number of AEDsa at KD initiation 2.4 (0–5)
Number of used AED before KD initiation 7.3 (4.0–14.0)
Number of patients with VNS treatment in the past 3 (9%)
Seizure frequency at KD initiation
Daily seizures 19 (56%)
1 seizure a week 10 (29%)
1 seizure a month 5 (15%)
Diet type
Classical, N (%) 8 (24%)
MCT N (%) 19 (56%)
Atkins, N (%) 2 (6%)
Mixed, N (%) 5 (14%)
a AED, anti-epileptic drug.
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(baseline and EEG at 6 weeks) were combined to calculate the
proportional reduction in % from the baseline index: (baseline index
minus index at 6 weeks/baseline index)*100. The IED index was also
calculated for the ﬁrst hour of sleep. The beginning of sleep was
deﬁned as the disappearance of the occipital rhythm during the
previous 5 min. When patients did not have an occipital rhythm, the
beginning of sleep was deﬁned as the disappearance of eye-blinks
during the previous 5 min. No IEDs were counted in the period of
30 min after any major seizure (tonic–clonic seizure, complex–
partial seizure, or tonic seizure) to avoid possible post-ictal changes.
Two EEGs from the same patient were scored directly after each
other. The reviewer was blinded for the clinical outcomes.
2.4.2. EEG scoring method 2
A second EEG reviewer randomly scanned several parts
throughout the EEG in the awake state and during the ﬁrst hour
of sleep. He concluded whether the EEG had the same, a lower, or a
higher number of IEDs compared to the other EEG of the same
patient. The reviewer was blinded for the clinical outcome.
We assumed that observed changes would be more reliable
when the results of EEG scoring method 1 and EEG scoring method
2 would be congruent. Furthermore, EEG scoring method 2
resembles the daily practice of patient care.
2.4.3. Background analysis
Because of the ambulatory registration, it was not possible to
obtain artefact-free EEG fragments in the awake state with eyes
closed for a spectral analysis. We only applied 3 global categories
by visual inspection to describe the baseline EEG. These were:
normal background, moderate background abnormalities (in-
creased amount of diffuse slow activity with a preserved occipital
rhythm with normal or decreased frequency), and severe
background abnormalities (diffuse slowing of the EEG and absence
of occipital rhythms).
2.5. Patient selection
We analyzed 34 patients, aged 1–45 years, included in the
prospective study between January 2005 and September 2010.
Initially, 45 patients with refractory epilepsy who were
candidates for the KD were included. In two patients an EEG
could not be performed because of a safety helmet in one and
behavioural problems in the other patient. One patient died of
epilepsy-related complications before the second EEG. In 7
patients, the second EEG was not registered because the diet
was discontinued within 6 weeks after the baseline EEG, as a result
of side-effects and/or the burden of the diet. In three patients, the
second EEG was recorded; however the diet was discontinued
before sufﬁcient clinical follow-up had been established as was
required in our study design, i.e. within two months after the 4-
week introduction of the diet. Of these three, one patient had
unacceptable gastro-intestinal side-effects. In the other two
patients, severe seizure aggravation, not expected from earlier
seizure observations (occurrence of at least twice as many seizures
in both patients and additional frequent non-convulsive epileptic
status in one of them), led to early discontinuation. We decided to
analyze these two patients as non-responders.
2.6. Statistics
We used Mann–Whitney U test (MWU) for calculating
differences between groups, Spearman’s correlations for correla-
tions between 2 variables, and Pearson Chi-square test (2-sided) to
test differences in proportions. Results were considered signiﬁcant
if alpha was 0.05.3. Results
3.1. Baseline data
The data of the 34 patients are shown in Tables 1a–1c. 62% of
the patients were children. 75% had at least several seizures a
week, and about half of the patients had one or more daily seizures
24 Patients were on the KD for at least 6 months, 8 patients
discontinued the diet between 2 and 6 months following the 4
weeks of KD introduction, and 2 patients discontinued the diet
between the end of the 4 weeks of KD introduction and 2 months
follow-up. Seizure diaries were complete for 25 patients at
baseline and 23 patients at follow-up. In 11 patients the clinical
response to the diet had to be deﬁned by the treating physician
because of incomplete diaries. 88% of the patients had IEDs in
the baseline awake EEG and 76% of the patients had IEDs in the
baseline sleep EEG. 21 Patients had no or only sporadic IEDs (1%)
at baseline in the awake state.
There was a trend towards correlation between baseline seizure
frequency and IED index (wakefulness Spearman’s R = 0.37
p = 0.07; sleep Spearman’s R = 0.36 p = 0.09). 76% of the EEGs
showed a moderate to severe background abnormality.
The severity of background abnormality was correlated to baseline
seizure frequency (Spearman’s R = 0.45 p = 0.02), and to baseline
IED index in wakefulness (Spearman’s R = 0.36 p = 0.04) and in
sleep (Spearman’s R = 0.35 p = 0.05).
3.2. Results after KD introduction
3.2.1. Seizure outcome
9/34 patients (26%) were clinical responders (50% seizure
reduction), of whom 7 were children. In 7 of the clinical responders
the response was diary-deﬁned, in 2 physician-deﬁned because of
an incomplete diary. They all had had a follow-up period of 6
months. The 7 responders with diaries showed a clear seizure
reduction from the second month of treatment which lasted until 6
months of follow-up, resulting in a mean seizure reduction of 50%
during 6 months, compared to the 2 months baseline period.
The mean baseline monthly seizure frequency in these 7
responders with diaries was 88.6 (SD 78.3) and in 16 non-
responders with diaries 60.4 (SD 84.0). Mean seizure frequency in
the follow-up period in 7 responders was 12.4 (SD 23.4) and in 16
non-responders with diaries 68.9 (SD 85.2). Mean age of clinical
Table 1b
Syndromal diagnosis.
Syndromal diagnosis Subtype/aetiology Number
of patients
Number of patients
(total of subgroup)
Percentage
Cryptogenic localization-related epilepsy 17 17 50%
Symptomatic localization-related epilepsy Perinatal asphyxia 3 14 41%
Bandheterotopia 1
Bacterial meningo-encephalitis 3
Trauma 1
Partial trisomy 14 and 8 1
Sturge Weber syndrome 1
CDKL-5 mutation 1
Perinatal intracerebral haemorrhage 1
Down syndrome 1
1p-syndrome 1
Symptomatic generalized epilepsy Myoclonic astatic epilepy (Doose syndrome) 2 2 6%
Undetermined epilepsies with both
generalized and focal seizures
Severe myoclonic epilepsy (Dravet syndrome) 1 1 3%
Total 34 34 100%
S.C.M. Ebus et al. / Seizure 23 (2014) 468–474 471responders was 10.9 (SD 12.1) and of non-responders 18.3 (SD
11.2). Mean duration of epilepsy in clinical responders was 6.6
years (SD 5.4) and in non-responders 13.0 years (SD 11.0).
There was no correlation between the clinical response to the
KD and baseline seizure frequency. There was a correlation
between the clinical response to the KD and younger age (R = 0.34
p = 0.05) and a trend towards correlation between the clinical
response and shorter duration of epilepsy (R = 0.31 p = 0.08).
3.2.2. EEG analysis at group level
A summary of the main ﬁndings is presented in Table 2. 31
patients were in a ketotic state on the day of the EEG. In 2 patients
ketosis was measured within the two days of the EEG and in 1
patient one week after the EEG. Since these values conﬁrmed a
ketotic state we assumed that this was also the case on the day of
the EEG.
AED daily doses were unchanged between the two EEG’s except
for one patient with a minimal dose reduction of one AED.
We did not ﬁnd correlations between the severity of EEG
background slowing at baseline or the IED index at baseline and
response to the KD. There was no correlation between the baseline
IED index and the % of seizure reduction.
We found a positive correlation between the % of IED reduction
in sleep at 6 weeks and the % of seizure reduction in the follow-up
period (Spearman’s R = 0.56 p = 0.04) (see Fig. 2) but not for IED
reduction in wakefulness (Spearman’s R = 0.2 p = 0.4).Table 1c
EEG baseline characteristics.
Categories Nr. of patients Mean IED indexa
IEDs in wakefulness
No IEDs in wakefulness 4 (12%) 0%
IEDs in wakefulness 30 (88%) 6.2% (SD 18.6%)
Sporadic IEDs (1%) 17 (50%) 0.15% (SD 0.18%)
Non-sporadic IEDs (>1%) 13 (38%) 16.1% (SD 28.0%)
IEDs in sleep
No IEDs in sleep 7 (21%) 0%
IEDs in sleep 26 (76%) 15.1% (SD 25.8%)
Sporadic IEDs (1%) 6 (17%) 0.50% (SD 0.28%)
Non-sporadic IEDs (>1%) 20 (59%) 24.7% (SD 21.5%)
Missing data 1 (3%)
Background abnormality
No 8 (24%)
Moderate 18 (53%)
Severe 8 (23%)
a Obtained by EEG scoring method 1.We did not ﬁnd a change in mean IED index after 6 weeks KD, in
either wakefulness or in sleep (n = 34 patients MWU wakefulness
p = 0.67, n = 33 patients MWU sleep p = 0.78). Mean awake IED
index at follow-up was 6.3% (SD 17.0%) vs. baseline index 6.3% (SD
18.6%) and mean sleep IED index at follow-up was 14.8% (SD 24.3%)
vs. baseline index 15.1% (SD 25.8%).
3.2.3. EEG analysis at individual level
In 4/34 patients, no IEDs were seen during the 24-h EEG at
baseline or at follow-up according to EEG scoring method 1 (2
responders, 2 non-responders). In the remaining 30 patients with
IEDs in wakefulness (7 clinical responders, 23 clinical non-
responders), and in the 26 patients with IEDs during sleep (7
clinical responders, 19 non-responders), we analyzed which
proportions of responders vs. non-responders had changes in
IED index at follow-up.
3.2.3.1. Individual analysis of the EEG in wakefulness. Disappearance
of IEDs in wakefulness according to EEG scoring method 1 was
observed in 6 patients (2 responders, 4 non-responders). They had
very low baseline IED indices between 0.01 and 1.22%. In these
patients with low baseline index, there was a discrepancy in
conﬁrming lack of IEDs at baseline or follow-up between EEG
scoring methods 1 and 2. EEG scoring method 2 conﬁrmed the lack
of IEDs at follow-up in 2 of the 6 patients identiﬁed by scoring
method 1. In these 2 patients, however, method 2 had not observed
IEDs in the baseline EEG either.
Twelve out of 30 patients (2/7 responders, 10/23 non-
responders) had a reduction (not disappearance) of IEDs according
to method 1. This did not distinguish responders from non-
responders (p = 0.48). EEG scoring method 2 conﬁrmed the
reduction of IEDs in 6 of these patients with proportional
reductions in excess of 20%. EEG scoring method 2 did not
distinguish between responders and non-responders (2/7 re-
sponders, 4/23 non-responders (p = 0.52).
Disappearance of IEDs or IED-reduction according to method 1
was observed in 4/7 responders with IEDs at baseline and in 14/23
non-responders (not signiﬁcant p = 0.86).
In order to compare our ﬁndings with the ﬁndings in the study by
Kessler et al,14 we examined which patients had a proportional
reduction of at least 10% in wakefulness according to method 1. This
did not distinguish the responders (4/7) from non-responders (13/
23) (p = 0.98). Nor could we distinguish between responders and
non-responders when higher proportional reductions were required.
3.2.3.2. Individual analysis of the EEG in sleep. Among the 26
patients with IEDs in sleep at baseline, there were no patients in
Table 2
Summary of ﬁndings.
Negative ﬁndings Positive ﬁndings
Group level No correlation between baseline IEDa index (wakefulness/sleep)
or EEG background disturbance and effect of KD
No signiﬁcant change in mean awake or sleep
IED index after 6 weeks KD
Seizure reduction in follow-up period correlated
with IED reduction in sleep EEG at 6 weeks KD
(R = 0.56 p = 0.04)
Individual level See results section EEG scoring method 1c
Proportional reductionb of 30% of IED index in
sleep correlated to effect of KD (p = 0.04)
EEG scoring method 2d
IED reduction in sleep correlated to effect of KD
(p = 0.04)
a IED, interictal epileptic discharges.
b proportional reduction = (baseline IED index minus index at 6 weeks/baseline index)*100.
c IEDs counted in ﬁrst hour of sleep.
d Global review (are IEDs reduced or not?).
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according to EEG scoring method 1 in 12/26 patients (5/7 responders
and 7/19 non-responders (p = 0.12). The 7 non-responders had a
higher mean baseline index (32.3% SD 24.8) than the 5 responders
(4.1% SD 4.3%), which was the attribution of 4 non-responders with
high baseline index in sleep between 18.9 and 87.9%. The other 3
non-responders were comparable to the responders with a mean
baseline index of 3.4% (SD 3.2%). Although these data seem to point
to a better result of the KD in patients with low IED index in sleep,
this was not proved (see above ‘‘EEG analysis at group level’’).
EEG scoring method 2 found a reduction of IEDs in 5/7
responders and in 5/19 non-responders, which was a signiﬁcant
difference (p = 0.04).
EEG scoring method 2 conﬁrmed the reduction of IEDs found by
method 1 in 9 of the 12 patients (4 responders, 5 non-responders).
In the 3 patients in whom EEG method 2 did not conﬁrm the IED
reduction, this was explained by a very low baseline sleep index
<1% in 2 patients (1 responder, 1 non-responder), and by a very
low IED reduction of 0.81% (proportional reduction 11.9%) in 1
patient with baseline index 6.9%.Fig. 2. Seizure reduction versus reduction in IED index, sleep. All (bold) dots on or below t
dots left of the vertical line are patients with IED reduction (according to EEG scoring We ﬁnally examined whether a certain proportional reduction
of the IED index during sleep could identify responders. We found a
signiﬁcant difference between responders and non-responders
when a proportional reduction of at least 30% was required, which
was observed in 4/7 responders vs. 3/19 non-responders (p = 0.04).
All these 7 patients also had proportional reductions in wakeful-
ness exceeding 20%. The syndromal diagnoses of the 4 clinical
responders with at least 30% proportional reduction in nocturnal
IED index were: cryptogenic localization related epilepsy n = 2,
symptomatic epilepsy after cerebral trauma n = 1, symptomatic
epilepsy after asphyxia n = 1. They were 3 children and 1 adult.
They all had focal interictal epileptiform activity.
3.2.3.3. Patients with increase in IED index. We examined whether
an increase in IED index would be observed more frequently in
non-responders than in responders. In wakefulness this was
observed in 3/7 responders and in 9/23 non-responders according
to EEG scoring method 1 (p = 0.86). EEG scoring method 2
identiﬁed 2/7 responders with increase in IEDs in wakefulness
vs. 8/23 non-responders (p = 0.76). Increase in IED index in sleephe horizontal line are patients with 50% seizure reduction (clinical responders). All
method 1). Spearman’s R = 0.56 p = 0.04.
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and 12/23 non-responders (p = 0.27). EEG scoring method 2
observed 11 patients (1 responder, 10 non-responders) with
increase in IEDs (p = 0.16).
4. Discussion
Nine of 34 patients (7 children and 2 adults) were clinical
responders, which represent a responder rate of 26% (33% in the
children, 15% in adults). There were no baseline EEG features that
characterized future clinical responders. At a group level we
identiﬁed a correlation between a nocturnal reduction of IEDs at 6
weeks and a seizure reduction in the follow-up period. More
relevant for clinical practice are changes in an early EEG at the
individual level. At six weeks, EEG scoring method 1 (IED counts)
found that a 30% proportional reduction of the IED index in sleep at
6 weeks, was seen more often in responders than in non-
responders. EEG scoring method 2 (global reviewing) also found
a signiﬁcantly larger proportion of patients showing IED reduction
in sleep within the group of clinical responders. The fact that the
two different types of EEG scoring methods found a signiﬁcant
correlation between IED reduction in sleep and clinical response,
adds to the reliability of ﬁnding this correlation. We observed that
global reviewing is less sensitive for the detection of changes. It
detected changes when spike-counts had resulted in 20% IED
reduction from baseline. The only clinical correlation we observed
was correlated with 30% IED reduction from baseline. Therefore,
global reviewing (as it is performed in clinical daily practice), may
be a good alternative for the time-consuming method of counting
individual spikes. We found however that for individual patients
the observation of reduction of IEDs in this study was not a very
powerful predictor, as this was also observed in 16% (method 1) to
26% (method 2) of the non-responders. We conclude that this
observation cannot reliably be used to advise patients whether to
continue or discontinue the diet.
We included a large proportion of patients with a low baseline
IED index in wakefulness. This explains why we found the highest
reductions of IEDs during sleep. In patients with a low baseline
index in wakefulness, there were large discrepancies in the
ﬁndings when EEG methods 1 and 2 were compared. This
illustrates that outcomes on changes in this group are less reliable
and are dependent on which samples of the EEG were assessed. It is
not likely that reviewing every page of the awake EEG of patients
with a very low IED index, would have produced a better
distinction between responders and non-responders. In patients
with higher baseline index (>1.22%) and with higher proportional
decreases in IED index (above 20%) the two scoring methods had
congruent results on detecting changes.
A weakness in studies with the EEG as outcome parameter is
that there is no information on ﬂuctuations of the IED index
outside the chosen duration of the EEG registration. We performed
a long-term EEG, but we were not informed on day-to-day
ﬂuctuations when treatment would not be changed. We cannot
exclude that a proportional reduction of at least 30% can be a result
of spontaneous ﬂuctuations.
In 6 other studies,4,14,16–19 IED frequency changes after KD were
analyzed and compared to a baseline. Only one study analyzed the
IED index during sleep (at group level) and found a signiﬁcant
reduction of IEDs at 3 months, as well as a positive correlation
between IED frequency reduction and seizures. This last observa-
tion corresponds to our ﬁndings. All patients in the 6 previously
published studies were children. Three studies examined individ-
ual EEG changes in responders vs. non-responders during
wakefulness. Remahl et al.17 described an IED reduction in 8/16
responders vs. 5/7 non-responders (not signiﬁcant). Dressler et al.18
found disappearance of IEDs in 9/25 responders vs. 1/24 nonresponders (p = 0.009). Kessler et al.14 found an individual IED
proportional index decline of 10% of the baseline index in 12/26
responders and in 2/11 non-responders (with a baseline median
spike index of 7.7). The timing and analysis of the EEG in this study
correspond fairly well to our method. We could not, however,
reproduce the same results for the EEG in wakefulness. Our patient
group had a much lower baseline median spike index of 0.2% (mean
6.2%) compared to the patient group of Kessler. In fact most cited
studies had included more patients with generalized, highly
frequent IEDs in wakefulness. Especially in patients with generalized
epilepsy syndromes such as Lennox–Gastaut syndrome, myoclonic
astatic epilepsy and West syndrome, highly frequent IEDs in the
awake state are usually observed. We only included 2/34 (6%) of such
patients, Kessler14 6/37 (16%), Remahl17 5/23 (22%) and Dressler18
15/50 (30%). Furthermore, Kessler classiﬁed a total of 18/37 (49%) of
patients with a ‘‘generalized electroclinical syndrome’’. Dressler
classiﬁed 46/50 patients with a ‘‘generalized epilepsy syndrome’’.
Finally, earlier studies included only children, this study also adults.
The differences in the epilepsy syndromes, EEG-types and ages
probably explain the different ﬁndings in the studies.
From the combined results of all studies, it is clear that
decreases in IED index can be found in a repeated EEG in individual
patients on the KD with some correlation with the effect of the KD.
Changes in IED index are best observed in patients with epilepsy
syndromes with high baseline IED index. The studies show
however that at an individual level, the method of performing
an early EEG to predict whether the patient will be a responder, is
not conclusive. Furthermore, in our study a clear and stable seizure
reduction in the clinical responders could already be observed in
the second month of KD treatment. Hence, in our patient group, an
early EEG at 6 weeks as a predictor of future seizure reduction, was
not necessary. Kessler14 commented that ‘‘the practical utility of
performing an early EEG as predictor, may be limited to those
patients whose seizure reduction on the KD is not immediate’’. The
number of patients with a delayed reduction of seizures in this
study was, however, not mentioned. There are several studies
conﬁrming that early seizure reduction (from the 1st month of
treatment) is seen far more often than delayed seizure reduction
(Coppola et al.1, Bergvist et al.20, Mosek et al.21).
In our study, we did not observe complete normalization of the
EEG in patients with a baseline IED index exceeding 1.22%. Some
studies mention abolition of frequent IEDs after KD, for example, in
patients with West syndrome and hypsarrhythmia.22,23 Nikanor-
ova et al.24 studied 4 children with CSWS (syndrome of continuous
spike waves in slow wave sleep) in whom IEDs were recorded
during sleep in 85% of the time. After 12 months of treatment, the
EEG had normalized in one patient, slightly improved in one
patient and not improved in 2 patients. The real ‘‘EEG-responder’’
showed a slight increase in IQ scores, disappearance of aggression
and an improvement in concentration at that time. When clinical
effects are subtle and not (yet) obvious, the normalization of the
EEG may encourage such patients to continue the KD. The
previously mentioned studies show that effects of the KD on the
EEG could be more profound in certain syndromes. In patients with
GLUT-1 deﬁciency (the best known indication for the KD),
reduction of IEDs was reported in all 4 patients who showed IEDs
at baseline, of whom 3 had >90% seizure reduction (1 had never
experienced seizures).25 The baseline frequency of IEDs and the
magnitude of the reduction were not mentioned in this study.
5. Conclusion
Although we observed a correlation between seizure reduction
and IED reduction during sleep at group level, we found no
evidence that early EEG changes predict the efﬁcacy of the KD in
individual patients. Only in certain patients, should EEG registra-
S.C.M. Ebus et al. / Seizure 23 (2014) 468–474474tion before and after KD still be considered. These are patients with
highly frequent interictal epileptic discharges which are a major
goal of treatment, such as patients with hypsarrhythmia or ESES
(electrical status epilepticus of slow wave sleep). In all other
patients, the observation of seizure reduction, which will most
often be noted early in the follow-up period, is the best parameter
for evaluating the effect of the KD.
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